

THRU ONLINE FILING

June 27, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code : 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Sub : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the 'Court of Justice of the EU' has upheld the fine of Euro 13.96 million (approx Rs. 125.62 crores) imposed by the 'General Court of the EU' collectively on Unichem Laboratories Limited (subsidiary company/Unichem) and Unichem's wholly owned subsidiary viz., Niche Generics Ltd (step-down subsidiary/Niche) with respect to patent dispute settlement agreement done by them for Perindopril drug matter with the innovator French Company Servier group.

It may be noted that because of this judgement there would be no material impact on the operations of Company. The Company and Unichem have already made provision of Rs. 125.62 crores in its book of accounts in respect of this litigation.

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Particulars	Information
Name of the authority	Court of Justice of the EU.
Nature and details of the action(s) taken, initiated or order(s) passed;	A fine of Euro 13.96 million collectively on subsidiary Unichem and step-down subsidiary Niche.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	June 27, 2024.

Ipca Laboratories Ltd.
www.ipca.com

<p>Details of the violation(s)/contravention(s) committed or alleged to be committed</p>	<ul style="list-style-type: none"> • The Servier group, whose parent company, Servier SAS, a French company developed Perindopril, a medicine used in the treatment of hypertension and heart failure; obtained a patent in 2004. • Following disputes in which the validity of the patent was challenged by many companies including Unichem/Niche, Servier entered into various settlement agreements with a number of generic companies including Unichem and Niche to settle the patent dispute. • It was alleged that as per Article 101 of TFEU, Unichem and Niche had acted in breach of EU competition law by agreeing to settle patent dispute with Laboratories Servier.
<p>Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible</p>	<p>A fine of Euro 13.96 million (approx. 125.62 crs.) has been imposed collectively on Unichem/Niche.</p> <p>Unichem and the Company had already made a provision of Rs. 125.62 crores in the books of accounts towards this fine.</p>

Please take this on record.

Thanking you

Yours faithfully

For Ipca Laboratories Limited

Harish Kamath
Corporate Counsel & Company Secretary
ACS 6792

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837